• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

    FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

  2. Roche Not Interested in Large Acquisitions, Says CEO -- Report

    Roche Not Interested in Large Acquisitions, Says CEO -- Report

  3. FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

    FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer

  4. Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

    Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

  5. Genentech to Buy Seragon Pharmaceuticals for up to $1.725 Billion

    Genentech to Buy Seragon Pharmaceuticals for up to $1.725 Billion

  6. Genentech to Buy Seragon Pharma For up to $1.725 Billion

    Genentech to Buy Seragon Pharma For up to $1.725 Billion

  7. Roche to buy Seragon for up to $1.725 billion

    Roche to buy Seragon for up to $1.725 billion

  8. Wide-Moat Funds That Fly Under the Radar

    These quality funds with smaller asset bases have portfolios built around solid companies.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.